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ORIGINAL ARTICLE
Lenalidomide treatment and prognostic markers in relapsed or
refractory chronic lymphocytic leukemia: data from the
prospective, multicenter phase-II CLL-009 trial
A Bühler1, C-M Wendtner2,3, TJ Kipps4, L Rassenti4, GAM Fraser5, A-S Michallet6, P Hillmen7, J Dürig8, SA Gregory9, M Kalaycio10,
T Aurran-Schleinitz11, L Trentin12, JG Gribben13, A Chanan-Khan14, B Purse15, J Zhang15, S De Bedout16, J Mei15, M Hallek3,17 and
S Stilgenbauer1
Efficacy of lenalidomide was investigated in 103 patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated on
the prospective, multicenter randomized phase-II CLL-009 trial. Interphase cytogenetic and mutational analyses identified TP53
mutations, unmutated IGHV, or del(17p) in 36/96 (37.5%), 68/88 (77.3%) or 22/92 (23.9%) patients. The overall response rate (ORR)
was 40.4% (42/104). ORRs were similar irrespective of TP53 mutation (36.1% (13/36) vs 43.3% (26/60) for patients with vs without
mutation) or IGHV mutation status (45.0% (9/20) vs 39.1% (27/68)); however, patients with del(17p) had lower ORRs than those
without del(17p) (21.7% (5/22) vs 47.1% (33/70); P= 0.049). No significant differences in progression-free survival and overall
survival (OS) were observed when comparing subgroups defined by the presence or absence of high-risk genetic characteristics. In
multivariate analyses, only multiple prior therapies (⩾3 lines) significantly impacted outcomes (median OS: 21.2 months vs not
reached; P= 0.019). This analysis indicates that lenalidomide is active in patients with relapsed/refractory CLL with unfavorable
genetic profiles, including TP53 inactivation or unmutated IGHV. (ClinicalTrials.gov identifier: NCT00963105).
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KEY-POINTS
● Overall response rate and survival outcomes are similar in
relapsed/refractory chronic lymphocytic leukemia patients
treated with lenalidomide irrespective of TP53 or IGHV
mutations.
● This suggests that lenalidomide activity may not be affected by
loss of functional TP53 or IGHV status.
INTRODUCTION
Single-agent lenalidomide has clinical activity in chronic lympho-
cytic leukemia (CLL), both in treatment-naive patients,1,2 and in
those with relapsed and refractory disease3–6 or unfavorable
characteristics.2,4,5
Recent clinical trials in CLL patients demonstrated that
unmutated IGHV is associated with unfavorable outcomes
with conventional chemotherapy or chemoimmunotherapy
regimens.7–9 Multivariate analysis established del(17p), TP53
mutation or unmutated IGHV were each important independent
prognostic factors for survival.7,9 TP53 mutation without
del(17p) is also of prognostic importance, with both markers
demonstrating independent prognostic significance in multi-
variate analyses.10
Patients with CLL having del(17p) had reduced overall response
rate (ORR) and progression-free survival (PFS) in a study involving
unselected CLL patients treated in routine clinical practice.11
Furthermore, the presence of del(17p) has been associated with
significantly inferior outcome in the context of novel, non-
cytotoxic treatments, such as ibrutinib.12
We investigated the efficacy of lenalidomide in subgroups of
relapsed and refractory CLL patients with high-risk genetics and
clinical characteristics at baseline.
MATERIALS AND METHODS
The study design and patient population are described elsewhere.13 In
brief, patients were randomized 1:1:1 to receive a double-blinded starting
dose of oral lenalidomide (5, 10 or 15 mg per day) on days 1–28 of each
28-day treatment cycle. Subject to tolerability, doses were escalated to a
maximum of 25 mg per day, with dose modifications applied as required.
All patients received appropriate prophylaxis for tumor lysis syndrome and
thrombosis. Treatment was continued until disease progression or
unacceptable toxicity. Institutional Investigational Review Board of each
participating site approved this study, which was conducted according to
good clinical practice and the ethical principles outlined in the Declaration
of Helsinki. All patients provided written informed consent.
Several exploratory analyses were conducted as part of the trial. Clinical
and demographic characteristics of interest were age, disease stage,
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number of prior treatments, presence of bulky disease or constitutional
symptoms and purine analog response status.
Blood samples for IGHV and TP53 mutation analysis, and fluorescence
in situ hybridization studies for interphase cytogenetic assessment were
collected pre-dose on day 1. All genetic analyses were performed centrally
(Ulm University, Ulm, Germany, or University of California, San Diego, San
Diego, USA), as described.9,10,14
Descriptive statistics were used to describe continuous demographic
and baseline variables for each patient; categorical variables were
summarized using frequency tabulations for treatment groups separately
and combined. Efficacy analyses were performed on the intention-to-treat
population and included all patients with genetic data available. For all
efficacy end points, determination of responses (including progression of
disease) was based on the investigator’s assessment of CLL response data
using International Workshop on CLL guidelines for diagnosis and
treatment of CLL.15 Responses by presence or absence of pretreatment
characteristics were compared using logistic regression stepwise selection.
Differences were considered significant at the Po0.05 level. Logistic
regression was done to assess the relationship of patient response
(responder vs non-responder) using stepwise selection. The following
baseline characteristics were included: relapsed vs refractory to last prior
therapy; IGHV mutation status; bulky disease; del(17p) and del(11q) status;
serum β2-microglobulin level; disease stage; and number of prior therapies
(o3 vs ⩾ 3).
Role of the funding source
Celgene Corporation funded the study. All authors had full access to all
data in the study and had final responsibility for the decision to submit for
publication.
RESULTS AND DISCUSSION
Of 104 patients enrolled, 103 received treatment; baseline
characteristics are described elsewhere and the primary results
demonstrated that lower starting doses of lenalidomide could
facilitate dose escalation, with indication of improved efficacy in
patients who escalated to higher doses.13
Based on the intent-to-treat safety population (n=103), data on
TP53 mutations, IGHV mutational status or del(17p) were available
for 96, 89 or 93 patients, respectively. TP53 mutations were
identified in 36 (37.5%) patients, unmutated IGHV in 68 (77.5%)
patients and del(17p) in 23 (24.7) patients.
Most patients with TP53 mutations also harbored unmutated
IGHV (27/36; 75.0%), whereas around half had del(17p) (17/36;
47.2%). In the absence of TP53 mutation, del(17p) was found in
5/60 (8.3%) patients. A majority of patients with del(17p) also had
TP53 mutations (17/22; 77.3%) or unmutated IGHV (16/22; 72.7%;
Supplementary Table 1). Patients with TP53 mutations, compared
with those without, were more likely to be 465 years (55.6% vs
33.3%), have del(17p) (47.2% vs 8.3%), have Rai high-risk/Binet C
disease (55.6% vs 39.3%) or to have a reduced (o1 50 000/mm3)
platelet count (75.0% vs 45.0%; Supplementary Table 1). Patients
with unmutated IGHV were more likely than patients with mutated
IGHV to have TP53 mutation (39.7% vs 20.0%) or bulky disease
(45.6% vs 25.0%). Patients with del(17p), compared with those
without, were more likely to have TP53 mutation (36.8% vs 15.0%),
Rai high-risk/Binet C disease (45.6% vs 35.0%) or a reduced
(o1 50 000/mm3) platelet count (77.3% vs 50.0%; Supplementary
Table 1).
Investigator-assessed ORR was 40.4% (42/104) for all patients
(Supplementary Table 2). Median time to first response to
lenalidomide for all patients was 3.3 months (range: 1.9–34.9).
The median response duration was 22.8 months (range:
16.6–29.3). ORRs for patients with and without TP53 mutation
were 36.1% (13/36) and 43.3% (26/60; P= 0.526); for patients with
and without mutated IGHV, ORRs were 45.0% (9/20) and 39.7%
(27/68; P= 0.796). ORR for patients with del(17p) was lower than
for those without deletions with borderline significance, using
Fisher’s exact test (21.7% vs 47.1%, P= 0.049; odds ratio: 0.31; 95%
confidence interval: 0.10 and 0.93). No other significant differences
were observed for any other characteristic assessed at baseline.
At a median follow-up time of 24 months, significant survival
differences were found between responders and patients with
stable disease (median PFS: 26.5 vs 7.2 months, Po0.001; median
overall survival (OS): not estimable vs 19.8 months; P= 0.011;
Table 1). The median PFS and median OS were 9.7 and
33.0 months, respectively, in the overall population. Median PFS
in patients with TP53 mutations, compared with those without,
was short with 11.0 vs 9.5 months (P= 0.665; Figure 1a); median
OS was 19.4 vs 35.4 months (P= 0.249; Table 1). For patients with
mutated vs unmutated IGHV, median PFS was 6.5 vs 10.4 months
(P= 0.607; Figure 1b); median OS was 31.9 months vs not
estimable (P= 0.293). In patients with del(11q) vs those without,
median PFS was 7.3 vs 17.6 months (P= 0.401; Figure 1c); median
OS was 21.3 vs 35.4 months (P= 0.435). In patients with del(17p) vs
those without, median PFS was 4.9 vs 11.0 months (P= 0.171;
Figure 1d); median OS was 18.9 vs 34.9 months (P= 0.318; Table 1).
Of note, although several of the observed differences between risk
groups were sizeable, no significant differences were observed as
Table 1. PFS and OS according to pretreatment characteristicsa
Characteristic N Median
PFS
(months)
P-valueb Median
OS
(months)
P-valueb
All patients 104 9.7 NE 33.0 NA
Responders 42 26.5 o0.001 NE 0.011
Patients with SD 31 7.2 19.8
Binet stage NA
Binet stage A 10 3.7 35.4
Binet stage B 28 15.3 37.7
Binet stage C 26 27.6 19.7
RAI staging system score NA
Low-risk disease 5 4.9 20.8
Intermediate-risk disease 14 19.6 NE
High-risk disease 21 8.0 28.5
TP53 mutation
Yes 36 11.0 0.665 19.4 0.249
No 60 9.5 35.4
del(17p)
Yes 23 4.9 0.171 18.9 0.318
No 70 11.0 34.9
del(11q)
Yes 28 7.3 0.401 21.3 0.435
No 65 17.6 35.4
IGHV mutation status
Mutated 20 6.5 0.607 31.9 0.293
Unmutated 69 10.4 NE
Number of prior treatments
o3 44 17.6 0.150 NE 0.019
⩾ 3 60 5.5 21.2
Bulky disease
Yes 45 10.6 0.339 33.0 0.689
No 58 9.7 34.9
Refractory to purine analogs
Yes 44 5.5 0.283 21.3 0.268
No 60 10.4 35.4
Abbreviations: NA, not applicable; NE, not estimable; OS, overall survival;
PFS, progression-free survival; SD, stable disease. aBased on intent-to-treat
population. bBased on unstratified log-rank test.
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the study was not powered to detect such differences between
risk groups.
Multivariable analyses were performed for PFS and OS including
baseline del(11q), del(17p), TP53 mutation, unmutated IGHV,
disease stage, relapse/refractory to prior purine analog therapy,
baseline β2 microglobulin, bulky disease and number of prior CLL
treatments as potential variables. Backward deletion was per-
formed at a significance level of 0.05 and the main effects with
P-values of ⩽ 0.05 were retained in the final model and were
identified as independent prognostic factors. Regarding PFS, none
of the factors were selected into the final model. Regarding OS,
only extensive pretreatment (⩾3 lines) significantly impacted
outcomes (median OS: 21.2 months vs not reached; hazard ratio:
0.51; 95% confidence interval: 0.28–0.90; P= 0.019).
Our data reveal that ORR and survival outcomes are similar and
relatively poor in relapsed and refractory patients with CLL
following lenalidomide treatment irrespective of the presence of
TP53 or IGHV mutations, suggesting that lenalidomide activity may
not be affected by loss of functional TP53 or unmutated IGHV.
Purine analog refractory status and disease stage, both the clinical
features associated with high-risk disease, did not appear to
impact ORR or survival outcomes following lenalidomide treat-
ment (Supplementary Table 2; Table 1).
In conclusion, our data indicate that a relatively modest
lenalidomide activity is seen in relapsed and refractory CLL
patients with unfavorable cytogenetic profiles, with ORRs of 36.1%
and 39.1% observed in patients with TP53 mutations and
unmutated IGHV, respectively. In patients with del(17p), ORR was
lower (21.7%) yet still apparent. However, in some patients, these
responses were durable as highlighted in the PFS and OS curves
(Figure 1). PFS and OS outcomes were similar irrespective of high-
risk genetic characteristics. The trial was not powered to detect
subtle differences between small subgroups, for example, with del
(17p) vs TP53 mutation. The pleiotropic effects of lenalidomide
observed on the tumor microenvironment16 or leukemia cell
proliferation17 and new insights into the various mechanisms of
action of lenalidomide are of increasing interest. These insights
may provide a rationale for specific combination regimens,
including lenalidomide plus ibrutinib, or other agents with distinct
mechanisms of action.
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